Drugs@FDA: FDA-Approved Drugs
Abbreviated New Drug Application (ANDA): 200626
Company: CIPLA
Company: CIPLA
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| ATAZANAVIR SULFATE | ATAZANAVIR SULFATE | EQ 100MG BASE | CAPSULE;ORAL | Discontinued | None | No | No |
| ATAZANAVIR SULFATE | ATAZANAVIR SULFATE | EQ 150MG BASE | CAPSULE;ORAL | Discontinued | None | No | No |
| ATAZANAVIR SULFATE | ATAZANAVIR SULFATE | EQ 200MG BASE | CAPSULE;ORAL | Discontinued | None | No | No |
| ATAZANAVIR SULFATE | ATAZANAVIR SULFATE | EQ 300MG BASE | CAPSULE;ORAL | Discontinued | None | No | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 08/09/2018 | ORIG-1 | Approval | Not Applicable |
Label is not available on this site. |
Supplements
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
|---|---|---|---|---|---|
| 08/07/2023 | SUPPL-3 | Labeling-Patient Package Insert, Labeling-Package Insert |
Label is not available on this site. |